NYSE
$323.28▼ 0.43%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.72BShares out 39.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.16After-hours26.10.17 08:364Ownership#●●●
Penumbra Inc
Insider Shruthi Narayan of Penumbra Inc filed a Form 4 on October 15, 2026, to report changes in beneficial ownership of securities. This filing serves as an official disclosure of insider stock transactions to the SEC.…more
$323.28-0.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17After-hours26.09.18 08:314Ownership
Penumbra Inc
Insider Shruthi Narayan of Penumbra Inc filed a Form 4 on September 17, 2026, reporting changes in beneficial ownership of securities as of September 15, 2026. This filing serves as an official notification to the SEC regarding the insider's equity transaction.…more
$323.28-0.43%vs prev closeView filingShare - 8.19After-hours26.08.20 08:234Ownership
Penumbra Inc
Penumbra Inc executive Narayan Shruthi filed a Form 4 on August 19, 2026, reporting a change in beneficial ownership of securities as of August 17, 2026. This filing serves as an official disclosure of insider equity transactions to the SEC.…more
$323.28-0.43%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.20 22:04Bullish#●●●#●●●
Penumbra Receives FDA Clearance for Lightning CAVT Technology to Treat DVT…more
Penumbra has received FDA clearance for its Lightning computer-assisted vacuum thrombectomy (CAVT) technology to treat deep vein thrombosis. The approval is supported by positive safety and efficacy data from the BOLT-DVT clinical trial.…more
$323.28-0.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6Pre-market26.10.06 22:12
●●●●●●●● ●●●●● ●●●●●●
Penumbra announced findings from a subset analysis of the STORM-PE trial, demonstrating a correlation between wearable-tracked daily activity and clinical recovery outcomes. The data, presented at the VIVA meeting, highlights the clinical performance of the company's treatment methods.…more
$323.28-0.43%vs prev closeShareBenzinga - 8.25Regular26.08.26 04:39
●●●●●●●● ●●●●● ●●●●●●
Incuvate has filed a patent infringement lawsuit against Penumbra in the U.S. District Court, alleging that the THUNDERBOLT system violates five of its patents. The legal dispute introduces potential uncertainty regarding the commercialization of Penumbra's recently launched neurovascular technology.…more
$323.28-0.43%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report